DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Phase 4

Conditions: Hematopoietic Stem Cell Transplantation

Interventions: Drug: ATG
Drug: CTX
Drug: Ciclosporin A (CsA)
Drug: Mycophenolate Mofetil
Drug: methotrexate (MTX)

First Posted Date: 2018-09-28

Last Posted Date: 2019-10-28

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 260

Registration Number: NCT03689465

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

and more 4 locations

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Phase 2

Conditions: Colorectal Neoplasms Malignant

Interventions: Drug: Bevacizumab and second-line chemotherapy
Combination Product: RFA, bevacizumab and second-line chemotherapy

First Posted Date: 2018-09-26

Last Posted Date: 2018-09-26

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 160

Registration Number: NCT03686254

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

Phase 2

Conditions: Minimal Residual Disease
Granulocyte Colony-stimulating Factor
Acute Myeloid Leukemia

Interventions: Drug: G-SCF

First Posted Date: 2018-09-11

Last Posted Date: 2018-10-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 122

Registration Number: NCT03665480

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Phase 2

Conditions: Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

Interventions: Biological: DLI
Combination Product: HMA+DLI

First Posted Date: 2018-09-07

Last Posted Date: 2018-09-07

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 100

Registration Number: NCT03662087

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Phase 2

Conditions: Brutons Tyrosine Kinase
FLT3-ITD Mutation
Acute Myeloid Leukemia

Interventions: Drug: Ibrutinib

First Posted Date: 2018-08-22

Last Posted Date: 2018-08-22

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 122

Registration Number: NCT03642236

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Phase 2

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Tyrosine Kinase Inhibitor
Minimal Residual Disease

Interventions: Drug: Tyrosine kinase inhibitor (TKIs)

First Posted Date: 2018-08-10

Last Posted Date: 2018-08-10

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 82

Registration Number: NCT03624530

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

Conditions: Risk-directed Therapy
Molecular Abnormality
Cytogenetic Abnormality
MRD

Interventions: Other: Justified risk stratification based on MRD after three course chemo therapy

First Posted Date: 2018-08-08

Last Posted Date: 2019-11-04

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 1000

Registration Number: NCT03620955

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure

Completed

Conditions: Post-hepatectomy Liver Failure

First Posted Date: 2018-07-26

Last Posted Date: 2024-11-14

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 591

Registration Number: NCT03598465

Locations: 🇨🇳
The first people's hospital of Foshan, Foshan, Guangdong, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
The second people's hospital of Shenzhen, Shenzhen, Guangdong, China

Injection Site Diversity Influences HA Distribution and Clinical Results in CP and KOA

Phase 4

Completed

Conditions: Hyaluronan
Osteoarthritis, Knee

Interventions: Procedure: anteromedial (AM) portal
Procedure: medial midpatellar (MMP) portal

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 164

Registration Number: NCT03600571

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Phase 2

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia

Interventions: Drug: Decitabine
Drug: Cyclophosphamide (CY)
Drug: Busulfan (BU)

First Posted Date: 2018-07-24

Last Posted Date: 2018-07-24

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 122

Registration Number: NCT03596892

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy